Adastra hires Quality Assurance Person, Priyanka Nalawade, Ph.D

July 12th, 2018 – Adastra Labs Holdings Ltd. (“Adastra” or the “Company”) announces Adastra Labs hires Quality Assurance Person, Priyanka Nalawade, Ph.D.  “Priyanka is a skilled PhD in Polymer Engineering with extensive experience as a lead R&D chemist and at extracting organic materials for use in the paint industry.  We are fortunate to bring her onto the Adastra Labs and Chemia Analytics teams,” reported CEO Andy Hale.

Dr. Nalawade is an enthusiastic and detail-oriented researcher. She attended the Institute of Chemical Technology (ICT), Mumbai, India where she earned a Bachelor of Technology in Polymer Engineering in 2010. She then moved to the USA, where she earned her Ph. D. in Polymer Engineering from the University of Akron, Ohio in 2015.  During her doctoral research, she synthesized and characterized novel high-performance polymers and reactive diluents obtained from renewable sources such as soybean oil and linseed oil.  Her work resulted in the development of low VOCs and environment-friendly paints.  After completing her PhD, she worked as a Senior R&D Chemist at Sherwin-Williams, USA where she focused on failure analysis and providing post-sale analytical support in the field of paints and protective coatings – from identifying weakness in products to analyzing field failures to developing new chemical characterization techniques for faster turnaround time on projects.  She led several high-value projects in collaboration with customers in North America, Europe and Asia. Dr. Nalawade recently relocated to Canada from the USA with her husband to utilize her organic and analytical chemistry expertise in the Cannabis industry.

Further Information

For further information, please contact:

Andy Hale, CEO

Email: info@adastralabs.ca

About Adastra Labs Holdings Ltd.

In Canada, Adastra (through its wholly owned subsidiary, Adastra Labs Inc.) is in the application process to become a Standard Processor under the Cannabis Act administered by Health Canada, with a licence to produce cannabis extracts. This licence will further enable Adastra and its subsidiaries to produce, package, sell (wholesale), and export medically focused and recreational cannabis extract and concentrate products in Canada to other licensed entities and internationally in jurisdictions where medical cannabis extraction products are legal.

The Company’s operations include a facility in British Columbia, Canada. The Company is developing its 13,035 square feet facility to be fully devoted to standard processing by late 2019, from which it expects to produce significant amounts of cannabis oil and/or hemp oil for the Canadian wholesale medical and recreational markets.

The Company will offer a suite of unique products under several existing consumer-focused brands, including tinctures, medicinal oils, concentrates, and when legalized, gel capsules and vaporizer pens. Through acquisition of existing cannabis extraction brands and careful development of its new brands, Adastra will be positioned to be a leader in branded, commercialized products in both the medical and adult-use markets across North America and internationally.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to:  Adastra’s expectations concerning an increase in its production capacity. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to general business, economic, competitive, political and social uncertainties. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Adastra assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Adastra Labs Holdings Ltd.

Scroll to Top